SmartLabs’ Post

GC01.1 kills #braintumor initiating cells (cancer stem cells) that are resistant to standard chemo and radiation therapy. This is one of the main reasons why we believe it can become part of the next standard of care for #glioblastoma. #GBM Watch our video to learn more: https://lnkd.in/efKzMZKu

🔊 It's great news that BlueRock received FDA Regenerative Medicine Advanced Therapy designation for Parkinson’s disease cell therapy candidate #bemdaneprocel. As of March 2024, the FDA had granted 109 RMAT destinations, of which only Neurocrine and Voyager's gene therapy (VY-AADC) was for Parkinson's disease. Here are some drugs that have been approved by the FDA via RMAT designation: ◾ Gene Therapy #Lenmeldy by Orchard Therapeutics, for the treatment of children metachromatic leukodystrophy ◾ Cell Therapy #Amtagvi by Iovance Biotherapeutics, Inc. Biotherapeutics, for the treatment of adult metastatic melanoma ◾ Gene Therapy #Lyfgenia by bluebird bio for the treatment of sickle cell disease ◾ Gene Therapy #Casgevy by Vertex Pharmaceuticals for the treatment of sickle cell disease ◾ Gene Therapy #Roctavian by BioMarin Pharmaceutical Inc. for the treatment of adults with severe hemophilia A ◾ Gene Therapy #Vyjuvek by Krystal Biotech, Inc. for the treatment of wounds in patients 6 months of age and older with dystrophic epidermolysis bullosa ◾ Tissue based therapy #Rethymic by Enzyvant Therapeutics for the treatment of Immune reconstitution in pediatric patients with congenital athymia ◾ Tissue based therapy #StrataGraft by Stratatech for the treatment of deep partial thickness burns ◾ Cell Therapy #Breyanzi from Juno Therapeutics/Bristol Myers Squibb for the treatment of adult patients with relapsed or refractory (R/R) large B-cell lymphoma

✨ 𝗙𝗗𝗔 𝗚𝗿𝗮𝗻𝘁𝘀 𝗘𝘅𝗽𝗲𝗱𝗶𝘁𝗲𝗱 𝗔𝗽𝗽𝗿𝗼𝘃𝗮𝗹 𝘁𝗼 𝗜𝗼𝘃𝗮𝗻𝗰𝗲 𝗕𝗶𝗼𝘁𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀 𝗔𝗺𝘁𝗮𝗴𝘃𝗶 𝗧-𝗖𝗲𝗹𝗹 𝗧𝗵𝗲𝗿𝗮𝗽𝘆 𝗳𝗼𝗿 𝗦𝗼𝗹𝗶𝗱 𝗧𝘂𝗺𝗼𝗿𝘀! 🌐 𝗜𝗻 𝗙𝗲𝗯𝗿𝘂𝗮𝗿𝘆 𝟮𝟬𝟮𝟰, The FDA authorizes Iovance Biotherapeutics, Inc. groundbreaking T-cell #therapy treatment 💉 for solid tumors. The "#Amtagvi" medication is the first tailored #tumor-infiltrating #lymphocyte (TIL) treatment available on the market. For patients with metastatic #melanoma who have previously had therapy with a PD-1 inhibitor—and a #BRAF inhibitor if the tumor possesses a BRAF V600 mutation—the FDA on Friday awarded it an expedited approval. Iovance is charging $515,000 per patient for the one-time therapy, which is the wholesale acquisition cost. The quoted price💲of the medication is somewhat more than that of the current CAR-T #cell treatments. 𝐁𝐫𝐨𝐰𝐬𝐞 𝐚𝐭 𝐨𝐮𝐫 𝐋𝐢𝐧𝐤𝐞𝐝 𝐑𝐞𝐩𝐨𝐫𝐭👉 https://bit.ly/42M63NI #tumor #immunotherapy #drugapproval #PD1Inhibitor #prophecy #maretresearch #prophecymarketinsights

Offering solution to our patients is paramount. 

Farnesyltransferase is an enzyme that plays a foundational role in many cellular pathways that drive the development and growth of different types of tumors. By inhibiting the enzyme’s function, we believe we can reshape treatment options for many cancers, through various mechanisms of action. KO-2806 is a potent next-generation inhibitor of farnesyltransferase designed to improve upon potency, pharmacokinetic, and physicochemical properties of earlier FTI drug candidates. Learn more about the FIT-001, opening in 2023: https://lnkd.in/gA53C9RR

July Featured Article: Novel therapeutics for small abdominal aortic aneurysms: Recommendations for rodent model research @honglu227 @curciAAA @BloodVesselDoc1 https://lnkd.in/gKbpZ93r

Protagonist's Chief Medical Officer Dr. Arturo Molina, MD, MS joined Talk! with Audrey to discuss the VERIFY Phase 3 clinical study of rusfertide, an investigational new drug being studied for patients diagnosed with PV, along with the common symptoms and challenges faced by PV patients. Watch the full interview here: #mpn | #hematology | #bloodcancer

Osteoarthritis is the most common form of arthritis affecting adults over the age of 60, leading to joint inflammation and pain. Our products use far-infrared technology to encourage cell growth and help reduce inflammation. Let Gladiator Therapeutics help accelerate the healing process so you can enjoy your days on the go. https://ow.ly/5Xtr50Pz4ul

KO-2806 is a potent next-generation inhibitor of farnesyltransferase designed to improve upon potency, pharmacokinetic, and physicochemical properties of earlier FTI drug candidates.

Ever heard of sarcoma? Sarcoma is a rare form of cancer that originates in bones and soft tissues, such as fat and blood vessels. In the United States, approximately 15,000 new cases are diagnosed each year. Understanding sarcoma is vital for its early detection and effective treatment strategies. 🦴💼 🩺 Medcare Pharma: Your Way to Cure Contact us: ☎️ | 1-866-4-MEDICINE 📧 | info@medcarepharma.care 🌐 | https://lnkd.in/gA9pPUVR #CancerAwareness #SarcomaFacts #clinicaltrial #clinicalresearch #medicalresearch #clinicalstudies #clinicalstudy #healthcare #medcarepharma #researchstudies